Sarepta Therapeutics (SRPT)
15.77
+0.46 (3.00%)
Upcoming Events
Latest Headlines
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Boor Kathryn Jean
June 5, 2026 8:11 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Mayo Stephen
June 5, 2026 8:10 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Wigzell Hans Lennart Rudolf
June 5, 2026 8:09 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: BEHRENS M KATHLEEN
June 5, 2026 8:08 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Connelly Deirdre P
June 5, 2026 8:07 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Nicaise Claude
June 5, 2026 8:04 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Chambers Michael Andrew
June 5, 2026 8:02 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Barry Richard
June 5, 2026 8:02 PM - SEC Filing
Form S-8 Sarepta Therapeutics,
June 4, 2026 4:56 PM - SEC Filing
Form 8-K Sarepta Therapeutics, For: Jun 04
June 4, 2026 4:30 PM - SEC Filing
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 3, 2026 8:30 AM - StreetInsider
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
June 1, 2026 4:30 PM - BizWire
Sarepta Therapeutics (SRPT) PT Lowered to $19 at Evercore ISI
May 15, 2026 7:15 AM - StreetInsider
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 13, 2026 4:30 PM - BizWire
Form 13F-HR Sarepta Therapeutics, For: Mar 31
May 13, 2026 4:23 PM - SEC Filing
Sarepta Therapeutics (SRPT) Tops Q1 EPS by 217c
May 6, 2026 4:46 PM - StreetInsider
Form 8-K Sarepta Therapeutics, For: May 06
May 6, 2026 4:11 PM - SEC Filing
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
May 6, 2026 4:05 PM - BizWire
Form 10-Q Sarepta Therapeutics, For: Mar 31
May 6, 2026 4:02 PM - SEC Filing
Form SCHEDULE 13G Sarepta Therapeutics, Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 1:10 PM - SEC Filing
Form SCHEDULE 13G Sarepta Therapeutics, Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
April 29, 2026 3:14 PM - SEC Filing
Form ARS Sarepta Therapeutics, For: Dec 31
April 24, 2026 4:22 PM - SEC Filing
Form DEFA14A Sarepta Therapeutics,
April 24, 2026 4:11 PM - SEC Filing
Form DEF 14A Sarepta Therapeutics, For: Jun 04
April 24, 2026 4:11 PM - SEC Filing
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
April 22, 2026 8:30 AM - BizWire
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026 8:30 AM - Globe NewsWire
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
April 17, 2026 6:46 AM - StreetInsider
Sarepta Therapeutics (SRPT) PT Raised to $20 at Evercore ISI
April 13, 2026 10:11 AM - StreetInsider
Sarepta Therapeutics (SRPT) PT Raised to $19 at RBC Capital
April 7, 2026 9:03 AM - StreetInsider
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2026 4:05 PM - BizWire
This stock's bull case is 'clearly stronger today than yesterday': analyst
March 27, 2026 7:00 PM - StreetInsider
Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: VANGUARD GROUP INC
March 27, 2026 1:00 PM - SEC Filing
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
March 26, 2026 6:39 AM - StreetInsider
Sarepta Therapeutics (SRPT) PT Raised to $13 at Citi
March 26, 2026 5:01 AM - StreetInsider
Barclays calls Sarepta Therapeutics (SRPT) data 'encouraging,' reiterates Equalweight rating
March 25, 2026 4:04 PM - StreetInsider
Sarepta Therapeutics (SRPT) PT Raised to $25 at Morgan Stanley
March 25, 2026 3:05 PM - StreetInsider
BofA Securities stays Underperform on Sarepta Therapeutics (SRPT): data update 'directionally positive'
March 25, 2026 3:02 PM - StreetInsider
Mizuho on Sarepta Therapeutics (SRPT): data de-risks siRNA platform, supports BIC potential
March 25, 2026 10:46 AM - StreetInsider
Wolfe Research stays Peerperform on Sarepta Therapeutics (SRPT) as data boosts RNA-focused narrative
March 25, 2026 10:43 AM - StreetInsider
Leerink Partners on Sarepta Therapeutics (SRPT): siRNA data 'a bit of a mixed bag'
March 25, 2026 10:33 AM - StreetInsider
Jefferies sees '+15-30% stock move' for Sarepta Therapeutics (SRPT) following data
March 25, 2026 10:32 AM - StreetInsider
Sarepta shares early clinical data from siRNA treatments for rare diseases
March 25, 2026 8:05 AM - StreetInsider
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
March 25, 2026 8:05 AM - BizWire
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
March 24, 2026 4:05 PM - BizWire
BofA Securities on Sarepta Therapeutics (SRPT): sNDAs 'positive first step' but regulatory risk continues
March 19, 2026 11:11 AM - StreetInsider
Jefferies: Sarepta (SRPT) sNDA filings to set stage for 25% stock move on FDA decision
March 19, 2026 10:57 AM - StreetInsider
Sarepta plans regulatory submissions for two Duchenne drugs by April 2026
March 19, 2026 8:30 AM - StreetInsider
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
March 19, 2026 8:30 AM - BizWire
Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
March 17, 2026 7:37 AM - StreetInsider
Full Article List
